Introduction
Core Team
Chief Scientist
Qiushi Chair Professor of Zhejiang University, Deputy Director of China National GeneBank. Professor Zhang got his Ph.D. degree from Kunming Institute of Zoology, Chinese Academy of Sciences in 2010. He was appointed as an assistant professor at University of Copenhagen in 2012 and as a tenured full professor in 2017. In 2022, he joined Zhejiang University as a full-time professor. Professor Guojie Zhang is an expert in biodiversity genomics and ecological evolutionary genomics and has made outstanding academic contributions with international influence in the fields. So far, more than 120 papers have been published in international high-impact academic journals, including 14 articles in Science, 8 articles in Nature, 6 articles in Nature Genetics, 1 article in Cell, and dozens of Nature research journals. Nearly 50 of them were published as first author or corresponding author. Many articles were selected as cover articles, and many others were selected as key recommended articles by F1000. Guojie Zhang has won several international awards and was selected as the cover character of the 2017 Nature Index. He has successively served as a judge for many national foundations such as the United States, Canada, France, Switzerland, the United Kingdom, Denmark, Sweden, Israel, etc., and has served as a manuscript reviewer for many top international journals including Nature, Science, and Cell. He is also as editorial Board member of GigaScience, Human Heredity, Zoological Research and the Encyclopedia of Life Sciences.
Senior scientist
Professor, Winner of National Science Fund for Excellent Young Scholars. Vice president of the The Fourth Affiliated Hospital Zhejiang University School of Medicine. Vice president of International School of Medicine, Zhejiang University. Professor Songmin Ying has long been dedicated in studies of molecular mechanism, pathology regulation and targeted therapy of diseases in respiratory system. His researches focus on molecular regulation mechanism of genomic stability of respiratory tumors and has made advances in chronic airway inflammation targeted therapy. Recent studies have been published in well-known academic journals as corresponding author and first author, including Nature, Nat. Cell Biol., Mol. Cell, Nat. Chem. Biol., Cell Res., Adv. Sci., Sci. Adv., Nat. Commun., Cell Disc., STTT, Nucleic Acids Res., JACI, Biomaterials, Cancer Res., and EMBO Rep. The total cited times is more than 4000. Professor Songmin Ying was invited to be a member of ERS College of Experts, and served as a reviewer of Worldwide Cancer Research、 British Lung Foundation、Marie Sklodowska-Curie Fellowship Programme、Danish Council for Independent Research and Czech Science Foundation.
Junior scientist
Director of the Scientific Research Department, Deputy Chief Physician. He is specialized in the diagnosis and treatment of corneal disease, glaucoma, ocular trauma, and strabismus amblyopia. He has been engaged in ophthalmology clinical and basic research for more than 10 years and has rich clinical experience in the diagnosis and treatment of ocular trauma, orbital, neuro-ophthalmic, and strabismus amblyopia diseases. He is also responsible for emergency rescue and treatment of various eye injuries, especially traumatic orbital injury, optic nerve contusion, and lacrimal duct injury. He was in charge of one national funds and three provincial funds, and was the major participant winning the first prize of Zhejiang Science and Technology Award and the first prize of Zhejiang Medical and Health Science and Technology Award.
Junior scientist
Chief nurse, doctor. Dr. Yang used to be the director of the Nursing Education Department of SIR RUN RUN SHAW Hospital, she is now assisting the construction of the Fourth Affiliated Hospital of Zhejiang University School of Medicine and as the master's supervisor of Zhejiang University Nursing and Huzhou Normal University, the doctoral supervisor of Zhejiang University Nursing, the backbone teacher of Zhejiang University Medical College, the deputy director of the Education Committee of the Nursing Society, the member of the American Association for Professional Development of Nurses, and the deputy leader of the foreign exchange group of the Nursing Branch of the China International Medical Promotion Association. Dr. Yang was the editorial board member of Nurse education in practice and Nursing and Rehabilitation, and as the reviewer for journals such as the Journal of Advanced Nursing, PLOS One, Chinese Journal of Nursing, Nursing and Rehabilitation, Chinese Hospital Management, and Chinese Modern Nursing. Dr. Yang's research field includes nursing education, chronic disease management, and health education. Since 2000, she has published more than 80 domestic core journal articles, including 10 SCI articles, and was responsible for the research of 7 department and bureau-level topics.
Junior scientist
Researcher of the "Hundred Talents Program" at Zhejiang University, doctoral supervisor. She received her postdoctoral training at The Jackson Laboratory for Genomic Medicine in the United States and joined Zhejiang University as a PI in December 2021. Her researches focus on epigenetics and 3D genomics by developing cutting-edge genomic technologies to decode the transcriptional regulation processes in diseases and development. She was a participant in genomic projects including ENCODE and 4DN. Her research achievements include the discovery of extrachromosomal circular DNA (ecDNA) in cancer as a mobile enhancer to promote the expression of chromosomal genes, and Sox2 regulating the self-renewal of neural stem cells by participating in the three-dimensional genome structure. The main research results were published in Cancer Cell, Cell Stem Cell, Trends in Cancer and others.
The Genomic Medicine Center focuses on the following research areas:
(1) Genome Structure and Functional Analysis：
We will build a ‘telomere to telomere’ reference genome for different ethnic groups in China and populations in countries along the "Belt and Road" as well as reference datasets and database for populational genomic structural variations, and then establish a functional genome reference database by comprehensively elaborating the impacts of variants on transcription regulation and genome spatial structure. We will collect clinical samples of tumors and reproduction-related diseases, perform comparison with normal populations in combination with clinical indicators, identify disease-related genomic variants for subclassification and marker variants determination, and finally establish genomic variants databases for different diseases.
(2) Genomic Medicine and Reproductive Health:
In collaboration with The Reproductive Medical Center, we will establish a genomic variants database focusing on reproductive diseases based on the associated analysis of genomic variation and clinical data from China and the "Belt and Road" populations.
Based on the populational genomic variations information from birth defect fetuses and their parents, the pathogenic loci of rare diseases or polygenic genetic diseases will be identified. On the grounds of these efforts, a genomic medical screening strategies as well as an automated analysis procedure will be developed for good prenatal and postnatal care.
(3) Pharmacogenomics and Oncology Precision Medicine:
In collaboration with The Oncology Medical Center, we will interpret the mechanisms leading to individual differences in drug responses through examining the genetic polymorphisms within drug-responsive genes and their sensitivity to drug treatment and provide guidelines to new drugs development. By investigating populational genomic variations in drug responses, we will develop personalized treatments and automated analysis pipeline. Combining populational genomic variations and clinical factors, we will design early detection strategies for health people at specific- or pan-cancer level and also an automated analysis procedure. Finally, we will popularize and commercialize the above precision medicine and cancer-screening program to strengthen the genomic medicine industry.